- Event Type: Q4 and FY26 Earnings Conference Call hosted by Confideleap Partners
- Event Date/Time: June 03, 2026 at 04:00 PM IST
- Purpose: Discussion of quarterly results and strategic update
- Management Participants: Mr. Punit Rasadia, Chairman and Managing Director
- Presentation Availability: The transcript will be hosted on the Company's website at https://www.anlon.in/reports.php?subid=15&name=Investor-Meet
- Financial Period Discussed: Q4 FY26 and Full Year FY26 (April 2025-March 2026)
- Compliance Statement: The document states this is a regulatory filing pursuant to Regulation 30 of SEBI-LODR Regulations, 2015
Financial Highlights:
- FY26 Consolidated Total Income: INR 172.22 crore (42.98% YoY growth from INR 120.46 crore in FY25)
- FY26 EBITDA: INR 47.77 crore (47.55% YoY growth)
- FY26 PAT: INR 29.09 crore (41.77% YoY growth)
- Q4 FY26 Total Income: INR 50.90 crore (vs INR 48.97 crore in Q4 FY25)
- Q4 FY26 PBT: INR 14.44 crore (vs INR 15.49 crore in Q4 FY25)
- Q4 FY26 PAT: INR 11.07 crore (vs INR 16.65 crore in Q4 FY25)
Strategic Updates:
- Capacity utilization at approximately 62% on consolidated basis
- Presence across 15 countries with 21 DMF filings
- Completed acquisitions of Apiqo Organics Private Limited (backward integration) and Bizotic Life Science (capacity expansion)
- Combined installed capacity expanded to 1400-1600 metric tons per annum
- Developing three molecules for two global innovators (CDMO opportunities)
- Diversification into industrial and fine chemical segment
Forward-Looking Guidance:
- FY27 Revenue Target: INR 380-400 crore
- FY28 Revenue Target: INR 700-800 crore
- EBITDA Margin Guidance: 25-30% range
- Plan to launch 7 new APIs in FY27
- File 3-5 additional DMFs in FY27
- Expected positive cash flow by end of FY27
- Capex Plan: INR 130 crore for new expansion (50-60% funded by term loan)
- Peak revenue potential of current capacity: INR 450-500 crore
Operational Metrics:
- Receivable days: 130-140 days on average
- Inventory: Maintaining 3 months inventory
- Working capital requirement expected to increase with growth
Additional Notes Section
- The document includes the full transcript of the earnings conference call with detailed Q&A session
- Multiple analysts participated including Disha, Paras Chheda, Ashish Parikh, Bhavesh Patel, and others
- Management addressed questions on margin pressures, acquisition integration, capacity utilization, and growth strategy
- The filing was digitally signed by Punitkumar Rameshbhai Rasadia, Managing Director